

# PRESS RELEASE

## Seraphim Capital Fund and Oxford Capital Partners invest further £1.2 million in Sirigen

**Date:**  
16<sup>th</sup> June 2009

**Location:**  
Hampshire;

**Sector:**  
Biotech / Life Sciences

**Turnover:**  
Not Disclosed

**Staff:**  
15

### Investors

Seraphim Capital and Oxford Capital Partners have invested a further £1.2 million into Sirigen - the company applying ground-breaking, Nobel Prize winning light amplification technology for use in the diagnostic and life science sectors. The round follows the £2 million previously invested in April 2008.

### Company

Sirigen uses novel light harvesting polymers to amplify the signal in a wide range of instrumentation and detection platforms used across the diagnostics and life sciences industries.

The Company's technology is used to enhance the sensitivity of tests and diagnostic assays by up to 100 fold and is being used by leading biomedical companies to both optimise existing diagnostic assays and to develop the next generation of diagnostic tools which will underpin the drive towards personal healthcare management.

The current round of investment has been completed as a result of the Company having achieved predetermined technical and commercial milestones.

With its core technology now fully developed, the Company has recently entered into commercial agreements with three leading global diagnostics companies.

This latest round of funding will enable the Company to optimise its production strategies to deliver upon customer specific applications each of which have market values in excess of \$100 million.

### People

Mark Boggett (Investment Director) from Seraphim Capital led the deal.

Rebecca Todd (Investment Manager) represented Oxford Capital Partners  
Nick Kerton (CEO) represented Sirigen Group Ltd.

### **Comment**

**Nick Kerton, CEO of Sirigen**

*"In the last few months we have successfully hit all our milestones, overcoming the key remaining technical hurdles. We are already working with some of the world's leading diagnostic companies who view our technology as being integral to their future growth. The strength of our current pipeline leads us to believe that our technology will soon become a 'must have' across the industry. This latest round of funding will help us deliver this."*

**Mark Boggett, Investment Director at Seraphim Capital**

*"In spite of the impact of the adverse economic climate, Sirigen has made tremendous strides over the last 12 months, entering into commercial agreements with several global leading diagnostics companies. This is testimony to the strength of its game-changing technology which now stands at the forefront of the next generation of innovation within the diagnostics industry. We are delighted to continue to support the Company as it goes from strength to strength."*

### **Advisers**

**Seraphim** - MBM Commercial (Legal) – Angus McGuire  
**Oxford Capital Partners** – Nabarro (Legal) – Barry Maytum

**Management** –  
**Company Solicitors** – Marriott Harrison – Jonathan Pearce

### **Editors' Notes**

**For further information please contact:**

**Seraphim Capital:**

Mark Boggett  
**e:** mark@seraphimcapital.co.uk  
**tel:** 020 7089 2318  
www.seraphimcapital.co.uk

**Oxford Capital Partners:**

Lucy Foster  
**e:** LFoster@oxcp.com  
**tel:** 01865 860760  
www.oxcp.com

**Sirigen:**

Nick Kerton  
**e:** nick.kerton@sirigen.com  
www.sirigen.com

**About Seraphim Capital**

Seraphim is an early stage venture capital fund that invests between £0.5 million and £2 million into high growth early stage UK businesses.

The Fund has been created through a collaboration of leading business angel networks. This provides the Fund access to a unique network of more than 1,000 leading business angels, consisting of some of the most successful and influential business leaders from across both the UK and America.

Seraphim's partners include Business Angel networks from across the country including London Business Angels, Pi Capital, Advantage Business Angels, Entrust and Archangels. The corporate venturers involved are The Summit Group and GLE. An exciting dimension to the Fund consortium is the addition of funding from Focus Enterprises a US investment bank and New Vantage Group one of the leading US Angel Groups. [www.seraphimcapital.co.uk](http://www.seraphimcapital.co.uk)

### **About Oxford Capital Partners**

Oxford Capital Partners is a science and technology venture capital firm with extensive experience in investing in and supporting businesses with high growth potential. Oxford Capital Partners looks for the best opportunities, backing exceptional entrepreneurs and investing across all stages of development, from start-up to IPO. Leveraging its extensive networks, Oxford Capital Partners assists portfolio companies in accessing international markets in Europe, the US, Middle East and Asia. Oxford Capital Partners is the manager of four Oxford Gateway Funds and oversees a portfolio of over 25 companies in a range of technology sectors, including ICT, clean technologies, life and physical sciences. Oxford Capital Partners was named Venture Capital House of the Year 2005 at the Unquote Awards.

### **About Sirigen Limited**

Sirigen's Nobel Prize winning technology harnesses the power of novel light-harvesting polymeric materials, offering High Sensitivity Fluorescence (HSF) amplification to detection in the diagnostic, life science and pharma marketplaces.

Sirigen's technology is platform agnostic and is capable of becoming the essential "Intel inside" application in the industry, bolting onto and improving current state of the art diagnostic systems.

Sirigen's Conjugated Polymer technology will improve the sensitivity of diagnostic testing platforms through assay improvement, thus driving the simplification and miniaturization of instrumentation and the relocation of appropriate diagnostic tests from the lab to near the patient

For more information: [www.sirigen.com](http://www.sirigen.com)